PortfoliosLab logoPortfoliosLab logo
CNCR vs. IBRN
Performance
Return for Risk
Dividends
Drawdowns
Volatility

Performance

CNCR vs. IBRN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and iShares Neuroscience and Healthcare ETF (IBRN). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

CNCR vs. IBRN - Yearly Performance Comparison


Returns By Period


CNCR

1D
0.00%
1M
0.00%
YTD
6M
1Y
3Y*
5Y*
10Y*

IBRN

1D
0.07%
1M
7.54%
YTD
3.07%
6M
22.58%
1Y
54.30%
3Y*
12.16%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


CNCR vs. IBRN - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than IBRN's 0.47% expense ratio.


Return for Risk

CNCR vs. IBRN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CNCR

IBRN
IBRN Risk / Return Rank: 8787
Overall Rank
IBRN Sharpe Ratio Rank: 8787
Sharpe Ratio Rank
IBRN Sortino Ratio Rank: 8888
Sortino Ratio Rank
IBRN Omega Ratio Rank: 7878
Omega Ratio Rank
IBRN Calmar Ratio Rank: 9090
Calmar Ratio Rank
IBRN Martin Ratio Rank: 8989
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. IBRN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and iShares Neuroscience and Healthcare ETF (IBRN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

CNCR vs. IBRN - Sharpe Ratio Comparison


Loading graphics...

Sharpe Ratios by Period


CNCRIBRNDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.88

Sharpe Ratio (All Time)

Calculated using the full available price history

0.37

Dividends

CNCR vs. IBRN - Dividend Comparison

CNCR has not paid dividends to shareholders, while IBRN's dividend yield for the trailing twelve months is around 0.96%.


TTM202520242023
CNCR
Loncar Cancer Immunotherapy ETF
0.00%0.00%0.00%0.00%
IBRN
iShares Neuroscience and Healthcare ETF
0.96%0.99%0.40%0.06%

Drawdowns

CNCR vs. IBRN - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum IBRN drawdown of -35.38%. Use the drawdown chart below to compare losses from any high point for CNCR and IBRN.


Loading graphics...

Drawdown Indicators


CNCRIBRNDifference

Max Drawdown

Largest peak-to-trough decline

0.00%

-35.38%

+35.38%

Max Drawdown (1Y)

Largest decline over 1 year

-11.97%

Current Drawdown

Current decline from peak

0.00%

-0.67%

+0.67%

Average Drawdown

Average peak-to-trough decline

0.00%

-10.18%

+10.18%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.37%

Volatility

CNCR vs. IBRN - Volatility Comparison


Loading graphics...

Volatility by Period


CNCRIBRNDifference

Volatility (1M)

Calculated over the trailing 1-month period

11.92%

Volatility (6M)

Calculated over the trailing 6-month period

19.63%

Volatility (1Y)

Calculated over the trailing 1-year period

0.00%

29.09%

-29.09%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

0.00%

25.37%

-25.37%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

0.00%

25.37%

-25.37%